¾È³çÇϼ¼¿ä. À̹øÁÖ Åä¿äÀÏ ¼¼¹Ì³ª ¹ßÇ¥ÀÚ ÀÌÁ¤Ã¶ÀÔ´Ï´Ù.
Á¦°¡ À̹øÁÖ ¹ßÇ¥ÇÒ ³í¹®Àº 2020³â 11¿ù PNAS¿¡ ÃâÆÇµÈ 'Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade'ÀÔ´Ï´Ù.
ÇØ´ç ³í¹®¿¡¼´Â anti-tumor therapy¿¡¼ Immune checkpoint blocking antibody¸¦ »ç¿ëÇÒ ¶§, ¹ß»ýµÇ´Â ºÎÀÛ¿ëÀÎ colitis¸¦ ¿ÏÈÇϱâ À§ÇÑ ¸ñÀû¿¡¼ À¯»ê±ÕÀ» ÀÌ¿ëÇÏ°í ÀÖ½À´Ï´Ù.
Anti-tumor therapy¿Í DSS administration ÀÌÀü, ±ÞÀÌÇÑ BifidobacteriumÀÇ ¿µÇâ¿¡ ÀÇÇØ gut microbiota º¯È°¡ ÀϾÀ¸¸ç, Lactobacillus°¡ Àå ³» composition¿¡¼ Áõ°¡ÇÔÀ» ¹àÇû½À´Ï´Ù.
ÀÌ·¯ÇÑ gut microbiome compositionÀÇ º¯È´Â colitis »óȲ¿¡¼ Intestinal T regÀÇ metabolic°ú suppressive functionÀ» Áõ°¡½ÃÄÑ immune homeostasis À¯Áö¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
Á¦°¡ ÀÌ ³í¹®À» ¼±Á¤ÇÑ ÀÌÀ¯·Î´Â ÇöÀç Á¦°¡ ÁøÇàÇÏ°í ÀÖ´Â ½ÇÇè¿¡¼ ÀÌ¿ëÇÏ´Â probiotics¿Í °ü·ÃµÈ ¸ÞÄ¿´ÏÁò ¿¬±¸¿Í ½ÇÇè µðÀÚÀο¡ µµ¿òÀÌ µÉ °Í °°¾Æ °øºÎÇغ¸¾Ò½À´Ï´Ù.
¿½ÉÈ÷ ÁغñÇÏ¿© Åä¿äÀÏ¿¡ ºË°Ú½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
³í¹®¸µÅ©: https://www.pnas.org/content/117/44/27509
- ´ÙÀ½±Û
- 11/20 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
- / °ü¸®ÀÚ
- ¾È³çÇϼ¼¿ä, À̹øÁÖ ¹ßÇ¥ÀÚ ´ÙÁ¤ÀÔ´Ï´Ù.
Á¦°¡ À̹ø¿¡ ¼±Á¤ÇÑ ³í¹®Àº 2018³â Cell reports¿¡ ÃâÆǵÈ,
'Suppression of Tcf1 by inflammatory cytokines facilitates effector CD8 T cell differentiation'ÀÔ´Ï´Ù.
À§ ³í¹®Àº transcription factorÀÎ Tcf1ÀÇ ¹ßÇöÀÌ T cellÀÇ effector differentiation¿¡ ¾î¶°ÇÑ..
- ÀÌÀü±Û
- 11/13 ¹ßÇ¥³í¹® ÀÔ´Ï´Ù.
- / °ü¸®ÀÚ
- ¾È³çÇϼ¼¿ä.
±â¼±ÀÔ´Ï´Ù.
À̹øÁÖ Á¦°¡ ¹ßÇ¥ÇÒ ³í¹®Àº 2019³â Cell host & microbe¿¡ ÃâÆǵÈ
'Commensal Enterobacteriaceae Protect against Salmonella Colonization through Oxygen Competition' ÀÔ´Ï´Ù.
º» ³í¹®Àº º´¾Æ¸®ÀÇSalmonella°¨¿° ½Ã ÇÊ¿äÇÑ factorµé°ú °ü·Ã ±âÀÛµéÀ» ¿¬±¸ÇÑ ³í¹®ÀÔ´Ï´Ù.
..